Publication date: Jan 17, 2025
It is now recognized that many patients have persistent symptoms after recovery from acute COVID-19 infection, an infection caused by the coronavirus SARS-CoV-2. This constellation of symptoms known as ‘Long COVID’ may manifest with a wide range of physical and cognitive/psychological symptoms. Few data are available on the prevalence, attributes, and factors associated with Long COVID in Africa. This was a retrospective review of patients’ electronic medical records from Hallelujah General Hospital (one of the first private hospitals to treat COVID-19 patients). The hospital’s database was searched for patients hospitalized for acute COVID-19 infection from March 2020 to December 2022. Two hundred and forty-seven participants who underwent follow-up beginning four weeks after symptom onset were assessed for Long COVID. Admission and follow-up data were collected using Kobo Toolbox and exported into SPSS 27 for analysis. The relationship between the independent and dependent variables was explored through binary logistic regression. One hundred seventy-eight (72. 1%) participants had at least one persisting symptom 4 weeks post-symptom onset, at a median follow-up time of 35 (IQR 32-40) days. The most frequently reported symptoms were fatigue (41. 7%), shortness of breath (31. 2%), cough (27. 1%), and sleep disturbances (15%). Duration of symptoms more than 7 days before admission [aOR = 1. 97; CI95% = 1. 04 to 3. 75; P = 0. 038] and length of stay more than 10 days in the hospital [aOR = 2. 62; CI95% = 1. 20 to 5. 72; P = 0. 016] were found to be significantly associated with Long COVID. There is a high prevalence of Long COVID among patients hospitalized for acute COVID-19. Those who had a longer duration of symptoms before admission and a longer stay in the hospital appear to have a higher risk.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | long covid |
disease | MESH | COVID-19 |
disease | MESH | infection |
disease | IDO | symptom |
disease | MESH | shortness of breath |
drug | DRUGBANK | Niflumic Acid |
drug | DRUGBANK | Coenzyme M |
disease | IDO | history |
disease | IDO | process |
pathway | REACTOME | Reproduction |
disease | MESH | sequelae |
disease | MESH | syndrome |
drug | DRUGBANK | Carbon monoxide |
disease | MESH | fibrosis |
disease | MESH | asthma |
pathway | KEGG | Asthma |
disease | MESH | hypertension |
drug | DRUGBANK | Oxygen |
disease | MESH | diabetes mellitus |
drug | DRUGBANK | Tropicamide |
disease | MESH | infectious diseases |
drug | DRUGBANK | Methionine |
disease | MESH | arthralgia |
disease | MESH | Chest pain |
disease | MESH | Anosmia |
disease | MESH | Ageusia |
disease | MESH | abnormalities |
disease | MESH | Anemia |
drug | DRUGBANK | Creatinine |
disease | MESH | pneumonia |
disease | IDO | protein |
disease | IDO | blood |